20.11.2024 07:00:58
|
Baloise is implementing its refocusing strategy – cash remittance of over CHF 550 million expected
Baloise Holding AG / Key word(s): 9 Month figures Basel, 20 November 2024. The first nine months of 2024 in brief:
Action steps under the refocusing strategy being implemented The sale of the portfolio of digital insurer FRIDAY, which was announced at the end of October, represented a further step in the new strategic direction. We anticipate that the sale of the FRIDAY portfolio, the related reversal of tax loss carryforwards, and write-downs resulting from the discontinuation of the ecosystem strategy will have a non-recurring negative effect of around CHF 100 million on profit for 2024. Of this amount, CHF 75 million is attributable to FRIDAY and CHF 25 million to write-downs in connection with the ecosystem initiatives. We do not expect the portfolio transaction or ecosystem divestments to have any further substantial adverse impact on earnings in 2025 or beyond. The volume of business in the first nine months of 2024 was on a par with the prior-year period at CHF 6,892.0 million (Q1–Q3 2023: CHF 6,943.5 million). It increased by 0.3 per cent in local currency terms and therefore achieved a similar growth rate to the first half of 2024. Adjusted for currency effects, there was a small decrease of 0.7 per cent. The volume of premiums in the non-life business rose by 2.9 per cent in local currency terms to CHF 3,428.3 million in the first nine months of 2024 (Q1–Q3 2023: CHF 3,372.4 million). The increase in Swiss francs was 1.7 per cent.
Combined ratio within the target range for 2024
EBIT in the life business expected to be significantly higher than CHF 200 million The volume of premiums in the life business declined by 3.5 per cent in local currency terms to CHF 2,748.5 million (Q1–Q3 2023: CHF 2,868.2 million). The decrease in Swiss francs was 4.2 per cent. As explained in the communications regarding the half-year financial results, the reduction was primarily attributable to the Swiss group life business, which is being affected by the ongoing trend towards semi-autonomous products and by the restrictive underwriting policy still being pursued in this sector. The semi-autonomous collective foundation Baloise Perspectiva maintained its encouraging growth trajectory and, as at the end of September, around 22,000 insured persons and 5,400 companies had signed up. The Group’s investment-type premiums improved by 3.7 per cent in local currency terms to CHF 715.2 million thanks to the relaunch of products in Belgium. The increase in Swiss francs was 1.8 per cent. EBIT in the life business was also at a healthy level in the first nine months of the year. We expect this segment to make a profit contribution of significantly over CHF 200 million. This is partly because the assumptions used to calculate the yield curve have been updated.
SST ratio of around 210 per cent and A+ rating from S&P confirm the strong capital base Despite the challenging nature of the current environment, Baloise is proving its credentials as a solid business with a strong capital base. The Swiss Solvency Test (SST) ratio stood at around 210 per cent as at the end of September 2024, which was the same level as reported in the half-year financial statements. Our comfortable capital adequacy was once again confirmed by S&P Global Ratings in June 2024, when it reaffirmed its rating of A+ for the Baloise Group. S&P rated Baloise’s capital strength as excellent and, in its credit rating report, underlined the Company’s very good market positions, strong technical performance and continued high level of capitalisation. Thanks to the optimisation of a Belgian run-off life insurance portfolio in the prior year, we are confirming a one-off cash remittance of CHF 62 million in 2024. This amount, combined with cash remittance from operations, means that Baloise anticipates a high level of cash remittance of more than CHF 550 million this year. Depending on the effective cash remittance at the end of 2024 and subject to the decision made about the dividend at the next Annual General Meeting, Baloise will consider a share buy-back of at least CHF 100 million next year.
Business volume as at 30 September 2024 (year to date)
* Investment-type premiums.
Further information Contact About Baloise End of Inside Information |
Language: | English |
Company: | Baloise Holding AG |
Aeschengraben 21 | |
4002 Basel | |
Switzerland | |
Phone: | +41 61 285 85 85 |
Fax: | +41 61 285 70 70 |
E-mail: | media.relations@baloise.com |
Internet: | https://www.baloise.com |
ISIN: | CH0012410517 |
Listed: | BX Berne eXchange; SIX Swiss Exchange |
EQS News ID: | 2033769 |
End of Announcement | EQS News Service |
|
2033769 20-Nov-2024 CET/CEST
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Baloise AG (N) (Baloise Holding)mehr Nachrichten
09.12.24 |
SPI-Papier Baloise-Aktie: So viel Gewinn hätte ein Investment in Baloise von vor 3 Jahren eingefahren (finanzen.at) | |
09.12.24 |
Veränderungen im Verwaltungsrat der Baloise Holding AG (EQS Group) | |
09.12.24 |
Changes to the Board of Directors of Baloise Holding Ltd (EQS Group) | |
02.12.24 |
SPI-Titel Baloise-Aktie: So viel hätten Anleger an einem Baloise-Investment von vor einem Jahr verdient (finanzen.at) | |
27.11.24 |
Reisen, Familie und finanzielle Sicherheit: Die Top-Lebensziele der Schweizer Bevölkerung (EQS Group) | |
27.11.24 |
Travel, family and financial security: the top life goals of the Swiss (EQS Group) | |
26.11.24 |
Charles Ischi AG gewinnt den InnoPrix SO! 2024 für zukunftweisendes Pharmaprüfgerät (EQS Group) | |
26.11.24 |
Charles Ischi AG wins the 2024 InnoPrix SO! award for its innovative pharmaceutical tester (EQS Group) |